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Chronic kidney disease (CKD) is a global public health concern and a key determinant of poor health 
outcomes. While the burden of CKD is reasonably well defined in developed countries, increasing 
evidence indicates that the CKD burden may be even greater in developing countries. Diabetes, 
hypertension, and obesity are major contributors to the global burden of disease and are important 
traditional risk factors for CKD; however non-traditional CKD risk factors, including nephrotoxin 
exposure, kidney stones, fetal and maternal factors, infections, environmental factors and acute kidney 
injury are also increasingly being recognized as major threats to global kidney health. A broad approach 
to CKD prevention begins with identification of CKD risk factors in the population, followed by 
development of appropriate mitigation strategies. Effective prevention policies rely on an accurate 
understanding of the incidence and prevalence of CKD in a given setting, as well as the distribution and 
burden of risk factors. Populations or individuals at risk for CKD must be screened and treated early to 
prevent onset and delay progression of kidney disease. Systematically collected data should be analyzed 
at country, provincial, and district levels to identify regional disparities and CKD “hotspots” and develop 
targeted prevention strategies. Race/ethnicity, genetics, sex, socioeconomic status, and geography are 
likely modifiers of CKD risk. A comprehensive, informed approach to prevention that takes account of all 
of these factors is therefore required to successfully tackle the global CKD epidemic. 
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Chronic kidney disease (CKD) is increasingly recognized as a global public health concern and an 
important contributor to morbidity and mortality.1 While the burden of CKD is reasonably well defined 
in developed countries, increasing evidence indicates that the CKD burden may be even greater in 
developing countries.1,2 Of the major contributors to the global burden of disease (GBD), diabetes, 
hypertension, and obesity, are traditional risk factors for CKD.1 Non-traditional CKD risk factors, 
including nephrotoxins (e.g. prescription medicines and alternative remedies), kidney stones, fetal and 
maternal exposures, infections, environmental exposures, and acute kidney injury (AKI) are also being 
increasingly recognized as major threats to kidney health:.3 The burden of CKD attributable to non-
traditional risk factors is unknown and may even predominate in low and middle-income countries 
(LMIC).  
 
A broad approach to CKD prevention begins with identification of the incidence, prevalence and 
distribution of risk factors followed by development of mitigation strategies. Populations or individuals 
at-risk for CKD must be screened and treated early to prevent onset and delay progression. Reducing 
CKD risk is also highly dependent on addressing the fact that it is both a consequence of and a 
contributor to socioeconomic disparities. This review discusses the globally-relevant major traditional 
and non-traditional risk CKD factors, highlights gaps in knowledge, and recommends strategies to close 
these gaps and enhance CKD prevention. Environmental risk factors are discussed elsewhere in this 
issue. 
 
Prioritization of CKD and detecting and investigating CKD hotspots  
To understand whether CKD is a priority within a country, incidence and prevalence, as well as the 
contribution of various risk factors to the burden of disease should be determined. Systematic and 
reliable data collection is required. It is important that such data are analyzed at region, country, 
provincial, and district levels to identify local disparities and CKD “hotspots”. For example, the GBD 
Study, has identified several hotspots in Central America where CKD prevalence is high and requires 
attention.4-6 These include Mexico, where women have one of the highest disability-adjusted life year 
rates for CKD (related to obesity, diabetes and hypertension), as well as pockets in Nicaragua, 
Guatemala and El Salvador where CKD of unspecified cause (CKDu) is highly prevalent in men, primarily 
related to non-traditional risk factors.6,7  
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To illustrate the importance of sub-regional local analysis, in Nicaragua, increased CKD rates in male 
farmers aged <60 years of age are associated with pesticide exposure, dehydration, alcohol 
consumption and exposure to heavy metals.8 Costa Rica has reported a higher incidence of CKD among 
young sugar-cane workers, with clinical and histological findings of chronic interstitial nephritis.9 In El 
Salvador, a high prevalence of CKD (17%) was observed among male farmers exposed to toxic 
pollutants.10,11. Studies in Sri Lanka reported an association between pesticide poisoning and pollutants 
with repeated episodes of AKI and CKD.12 In India and Pakistan, a large percentage of CKD cases are of 
undetermined etiology potentially related to environmental factors.13 Many knowledge gaps remain 
regarding these regional CKDu epidemics.4  
 
Gaps: There are no reliable statistics about prevalence of CKD in most of the developing world. 
Improving and expanding local data collection, processing and research infrastructure is recommended 
to ensure better understanding of the burden and regional distribution of specific CKD risk factors. 
 
Action strategies: Including screening for kidney disease in established non-communicable disease (NCD) 
risk factor surveys would add significant value to existing efforts to monitor NCD risk-factor prevalence, 
likely at lower cost than duplicating efforts with parallel CKD surveillance programs. Combining such 
survey data with global positioning technology would permit identification of regional and local 
variations in CKD occurrence. For example, the World Health Organization (WHO) STEPwise approach to 
surveillance (STEPS) is an NCD household survey launched in 2002.14 To date, 122 countries have 
participated.15 Depending on local resources, the survey collects behavioral risk factors (Step 1), physical 
measurements including blood pressure (BP), height and weight (Step 2) and biochemical parameters 
(blood glucose and lipids, Step 3).16 Advocacy efforts in Uruguay succeeded in gaining inclusion of serum 
creatinine and urine protein measurements in the STEPS Survey in 2006. This effort captured the 
attention of policy makers and resulted in a policy mandating kidney disease screening in individuals 
with hypertension or diabetes at regular health check-ups in the employed population. This program is 
raising CKD awareness and will permit tracking of prevention efforts.17  
 
Importantly, surveillance or outreach activities must include vulnerable groups and ensure equitable 
representation of the population. Monitoring activities should integrate national data at regional and 
local levels with data obtained in research and screening activities to optimize efficiency, facilitate 
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surveillance, and permit rapid identification of geographic “hotspots” for CKD that require focused 
attention.18 A task force supported by global experts should be set-up to investigate hotspots rapidly. 
Investigations should include standardized data on social, structural, and clinical risk factors, clinical 
course, and potential interventions. A guideline-based approach should be disseminated and adapted in 
regions experiencing CKD hotspots. An example is the international study group on CKDu in 
Mesoamerica, organized by the Central American Program for Work, Environment and Health.19 Such 
efforts require a multi-sectoral approach with sustainable financing.20  
 
Tackling CKD risk factors: diabetes, hypertension and obesity 
The WHO Global Action Plan for the prevention and control of NCDs does not include CKD among the 
four priority NCDs. However, diabetes, hypertension and cardiovascular disease (CVD) are 
acknowledged as integrally linked with CKD. Notably, CKD is an important risk amplifier within these 
conditions.21 Across the world, 415 million adults are living with diabetes, 1.4 billion adults have 
hypertension, and 2.1 billion children and adults are overweight or obese.22-24 The prevalence of CKD in 
adults with type 2 diabetes is approximately 25-40%, depending on population factors.25-27 In the United 
States, the prevalence of CKD is approximately 30% among adults with hypertension, and 17% among 
obese adults.25 The size of the population at-risk of CKD is influenced by regional differences in 
demographics, different approaches to diagnosis and management, and the effectiveness of local 
interventions to address lifestyle-related risks. Reduction of lifestyle-related risks is a cornerstone of 
mitigating the public health impact of diabetes, hypertension, and obesity. There is clear evidence 
linking upstream factors such as poor diet, poverty, food insecurity, tobacco consumption and other 
lifestyle factors with risk of developing CKD.28-35 Conversely, interventions to manage hypertension and 
promote weight loss are associated with reduced risks of developing CKD and better outcomes among 
those living with CKD.2,36-42 
 
Gaps: Epidemiological assessment, followed by prioritization of CKD risk factors according to their 
contribution to the local burden of disease, is important to determine where public health efforts should 
be focused to reduce the population burden of CKD. In addition, existing barriers to implementation of 
locally-relevant strategies for prevention and management of diabetes, hypertension and obesity must 
be identified. Barriers may include resistance to change in the communities themselves or push-back 
from industry and others potentially impacted by for lifestyle modification campaigns.  
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Action strategies: Population-based studies are needed to determine the impact of diabetes, 
hypertension, and obesity prevention programs on CKD prevalence and incidence. Longitudinal studies 
are necessary to understand the impact of prevention programs on rates of CKD and end-stage kidney 
disease (ESKD) and related comorbidities including cardiovascular complications and infections. Studies 
are required to better understand the appropriate risk-benefit thresholds (target hemoglobin A1c, BP, 
weight) for CKD prevention and management, and to understand interactions between race/ethnicity, 
genetics, socioeconomic status, and geography as modifiers of CKD risk and progression. The impact of 
tobacco consumption on CKD requires further study. 
 
Strategies to reduce CKD risk attributable to diabetes, hypertension and obesity will be most effectively 
implemented as part of a broad approach to NCD prevention. Interventions to reduce lifestyle related 
NCD risk factors are most successful when implemented at both patient and community levels, 
supported by legislation and regulation.43 Public health approaches with the greatest evidence of 
effectiveness in reducing NCD risk include economic incentives to lower prices of healthy food, taxation 
on unhealthy food, education and physical activity programs in schools, food advertising restrictions and 
standards, providing more recreation spaces and facilities, sustained media campaigns for smoking 
cessation, cigarette packet warnings, restrictions on tobacco advertising, higher taxes on tobacco and 
restrictions on smoking in public areas and workplaces.44 Several countries have made efforts to reduce 
population consumption of sugary beverages, high fat foods, and salt with the endorsement of 
Panamerican Health Organization and the WHO, however more research is needed to understand what 
lifestyle interventions will have the greatest impact on the CKD burden.21,45,46  
 
An example of the importance of rigorous epidemiologic evidence required to inform policymaking and 
action, is the on-going debate on the utility of sodium reduction as a population measure to reduce BP 
and CVD.47-52 Recent studies have demonstrated a J- or U-shaped relationship of sodium intake with BP 
and mortality.53-55 The benefit of salt reduction is greater among hypertensive people, but definitive 
effects on kidney disease outcomes remains uncertain. Interventional studies have demonstrated that 
estimated glomerular filtration rate (eGFR) and albuminuria (proteinuria) increase with higher salt 
intake, and a recent study showed that reduction of sodium intake reduced albuminuria.56 In the United 
Kingdom, voluntary food manufacturing targets achieved a lower sodium intake of 15% between the 
years 2001 and 2011 that was associated with a decrease in mean BP (3 mmHg) and 40% reduction in 
deaths from stroke and ischemic heart disease.49,57 However, the respective role of sodium reduction 
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versus other treatments for hypertension, dyslipidemia, and CVD are not clearly delineated.49,57  
 
Implementing population-level approaches to reduce NCDs requires action across multiple sectors of 
government and society, as well as commitment of governments. This is consistent with the “Health in 
All” policies strategy outlined by the WHO, which emphasizes the importance of multi-sectoral 
engagement to the successful implementation of public health policies.43,45 At the level of health 
departments, healthcare care providers must have the necessary technology, tools, medicines and 
services required for efficient assessment and control of risk factors. Community engagement and 
education are crucial to optimize success. Patients themselves are also key to NCD prevention. In the 
Chronic Care Model, patient self-care takes on great importance, while the roles and responsibilities of 
physicians, nurses, and community health workers are being redefined through innovative strategies 
and technologies.20 Ongoing monitoring and evaluation of policy implementation will permit better 
understanding of barriers to and facilitators of CKD prevention. This is especially true of LMIC, where 
major barriers are quality, price and availability of drug treatments for diabetes and hypertension. 
Understanding how such barriers and facilitators vary by jurisdiction, health system, race/ethnicity, age, 
sex, and socioeconomic status help to inform development of effective local strategies.   
 
Systematic surveillance is recommended to screening for diabetes, hypertension and obesity, using the 
STEPS survey model for example. Once individuals with these conditions are identified, they should be 
recognized as being at high-risk of CKD and have eGFR and albuminuria measured. Clinical guidelines on 
blood pressure, blood glucose, weight and physical activity targets should be clear and easily 
implementable to optimize CKD risk-factor management. Screening and early intervention when CKD is 
detected have been shown to reduce ESKD and be cost-effective.39,58-60  
 
Nephrotoxins as risk factors for AKI and CKD  
Nephrotoxic agents can cause both AKI and CKD.61 Nephrotoxin exposure is common in hospitalized 
patients and may account for up to 25% of AKI.62-64 Common agents associated with AKI include non-
steroidal anti-inflammatory drugs (NSAIDS), antibiotics, iodinated contrast media, and 
chemotherapeutic drugs.65,66 Clinician and patient education are important to reduce risk of 
nephrotoxicity. Where electronic medical records (EMR) exist, alerts to reduce risk of nephrotoxic 
exposure and drug interactions can be activated.67,68 EMR can simultaneously be used to monitor 
prescription practices, responsiveness to alerts and prompts, rates of AKI, and barriers to effective 
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implementation.69,70 In high-income countries, AKI typically develops during hospitalization and may 
impact long-term health. For example, evidence of CKD (urinary abnormalities, low eGFR, or 
hypertension) was found in 70% of children 6 months after nephrotoxin-induced AKI.71  
 
The list of medications that can induce CKD is steadily expanding. The mechanisms range from 
interstitial inflammation to glomerular and tubular injury.72-74 Strategies should be implemented to 
reduce nephrotoxin-induced AKI and CKD, as well as emphasizing risks of medication over-use and dose-
adjustments for eGFR. Detection of medications that lead to CKD is challenging given the long time 
dimension. As recently described for proton pump inhibitors, linkage of clinical and prescription 
databases can identify novel links between CKD and medication that enables ongoing surveillance.72 
 
Use of culturally-traditional and alternative remedies is common worldwide, reaching over 80% of the 
population in many regions.75 The rates of associated AKI and CKD are unknown, although up to 30% of 
AKI in sub-Saharan Africa may be related to traditional remedy use.76 In Europe and North America, the 
market for alternative remedies generates billions of dollars per year.77 Remedy production is often 
unregulated leading to high inter-product variability and underappreciated risk of kidney injury.78 In 
LMIC, traditional remedies are often the only affordable means of healthcare. Given the large numbers 
of people worldwide using theses remedies, toxicity cannot be universal, but instead may relate to 
individual susceptibility which remains under-investigated.75  
 
Gaps: The true risk of nephrotoxicity of commonly used medications or remedies is uncertain given the 
unknown denominators of use. Some medications are known to be nephrotoxic, especially in particular 
circumstances e.g. NSAIDS with volume depletion. The magnitude of risk, which compounds are most 
toxic and under which circumstances, and how best to use these compounds safely if no alternative 
exists remain unknown. In LMIC traditional medicines are used for many reasons other than medical, 
therefore better understanding is required of the role remedies play in people’s lives.79 Further studies 
are required to identify potentially toxic remedies, risk factors that may exacerbate nephrotoxicity, 
herb-medication interactions and potentially beneficial compounds.80-86 
 
Action strategies: In settings with EMR, use of medicines and alternative remedies should be captured. 
These databases would permit monitoring of prescription practices to establish a true denominator of 
subjects “at risk” and permit surveillance to determine associations with nephrotoxicity and potential 
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exacerbating factors. Screening protocols should be developed to identify nephrotoxic effects of 
medication to improve consistency in case/compound identification and comparability of outcomes. 
When nephrotoxicity is suspected, attempts should be made to analyze culprit remedies and detailed 
case reports should be published. Education of health care practitioners is important to foster regular 
prescription reviews. Guidelines should emphasize measurement of eGFR prior to prescription of 
potentially nephrotoxic medication with electronic warnings for medication interactions and risks. 
Shared pharmaceutical prescription databases would avoid repeat prescriptions or drug interaction 
potential. Research should continue to develop effective alternative agents with reduced nephrotoxicity. 
 
To reduce use of nephrotoxic remedies, it is important to ensure that individuals have access to 
essential medical care and medication. Where alternative remedy use is widespread, strategies should 
be identified to minimize exposure to nephrotoxins. Such approaches should be customized based on 
region, economic realities, and community perspectives to improve safety without alienating groups or 
challenging fundamental beliefs. Engagement with traditional healers is crucial to foster collaboration, 
educate about kidney disease, and to learn about potentially beneficial remedies. The public and 
healthcare workers (HCW) must be educated about nephrotoxicity and drug interactions relevant to 
herbal remedies and over-the-counter preparations.86 Clinicians should be encouraged to ask about 
alternative remedy use. A global free web-based adverse event reporting (across income settings) site 
should be developed to gather data and study associations of remedy use with rates of CKD.  
 
Given easy access to alternative remedies, governments should develop policies about accuracy of 
advertising and health claims touted on the Internet and require efficacy data similar to that required of 
pharmaceuticals. Policies should enforce minimum standards of safety, manufacture, labeling and 
adverse event reporting on the alternative remedy industry.  
 
Kidney stones and risk of CKD  
Kidney stone disease is now recognized as a chronic health condition that is associated with risks of CKD 
and ESKD.87-91 The association between kidney stones and CKD is partly explained by shared risk factors, 
such as diabetes92-94, obesity95,96, hypertension93,96,97, metabolic syndrome98,99 and CVD100-102.  However, 
kidney stones may also directly contribute to CKD development and progression via urinary tract 
obstruction and/or infection, nephrocalcinosis, and oxalate nephropathy.87,103,104 The worldwide 
prevalence of kidney stones among adults is 5-9% and apparently increasing, with variation between 
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regions and countries.105,106 The rising global rate of kidney stones may be contributing to the overall 
CKD burden related to dietary factors, obesity, global warming, and environmental and occupational 
exposures (e.g. high ambient temperatures, contact with zinc or cadmium).89,96,104,106 Individuals who 
have experienced a single stone event are at increased risk for a symptomatic stone recurrence (up to 
50% within the first 5 years).104 Therefore, prevention among these individuals is an important strategy 
to reduce further stone and CKD risks.89 Higher fluid intake, avoidance of low dietary calcium and 
sweetened beverages, and reduction of dietary sodium and red meat intake reduce stone risk.107-109  
 
Gaps: Better understanding of regional risk for kidney stones is important to prioritize stone prevention 
and reduce CKD risk. The regional impact of climate change on kidney stones is unknown. Long-term 
surveillance should permit better understanding of the impact of stone prevention strategies (lifestyle 
habits and medication) and treatments (e.g. lithotripsy, surgery) on risks of new-onset and progressive 
CKD. Healthcare costs for kidney stone disease require further study. The effectiveness and cost-
effectiveness of prevention strategies across populations are unknown. 
 
Action strategies:  Tracking mechanisms and research should be developed to determine relationships 
between kidney stones and CKD incidence, prevalence, progression and complications in regional 
contexts. Environmental or occupational “hot spots” should be detected through surveillance. 
Understanding stone types and risk factors (e.g. genetics, infections, diet) are important to inform local 
prevention strategies. In concert with public health strategies to reduce diabetes, hypertension and 
obesity, surveillance activities should include impact on rates of kidney stones and of stone-related CKD 
to identify high-risk groups for targeted prevention and cost-effectiveness.89 In high stone-risk areas, 
public and HCW education campaigns should increase awareness and simple prevention strategies (e.g. 
fluid intake, dietary modification). Where occupational exposure is detected as important, engagement 
with policy makers and employers is important to modify work conditions.110  
 
Maternal, fetal and childhood health as risk factors for CKD 
Low birth weight (LBW), small for gestational age (SGA), and preterm birth (PTB) impact the number of 
nephrons an individual starts life with, and are increasingly being recognized as CKD risk factors.111,112 In 
2010, over 43 million babies in 139 LMIC were born too soon or too small, suggesting many children are 
born at-risk of CKD.113 Developmental programming for CKD results from many structural, 
environmental, social and physical factors that impact maternal and fetal health throughout pregnancy 
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as well as the child’s nutrition and growth.111 Recent evidence also points to high birth weight (HBW, 
especially an infant of a diabetic mother), in addition to LBW and PTB, to be a risk factor for obesity, 
hypertension, diabetes and CKD.114-118 Early onset of diabetes in offspring associated with intrauterine 
diabetes exposure is partly responsible for the earlier development of CKD and ESKD in the 
offspring.114,119 Childhood obesity is also an important risk amplifier for CKD after LBW, SGA or PTB.120 
Preterm babies are at increased risk of AKI related to reduced nephron number, frequent nephrotoxin 
exposure and co-morbidities which increase their risk of subsequent CKD.121,122 Not only the children of 
troubled pregnancies are at long-term risk of CKD however. Women who developed pre-
eclampsia/eclampsia have a higher life-time risk of hypertension, CKD and CVD and those who 
experienced gestational diabetes (GDM) have an increased risk of developing diabetes.123-125 Pre-
eclampsia occurs in 1-5% of pregnancies worldwide and GDM occurs in around 2-6% of pregnancies in 
Europe but in up to 25% in some LMIC.124-126 Many individuals at long-term risk of CKD can be identified 
early, in prenatal clinics and delivery rooms. 
 
Gaps: The contribution of maternal and fetal risk factors to the CKD burden is unknown. In vivo counting 
of nephron number is not yet possible and poses an obstacle to further understanding developmental 
programming in the kidney. Variability of nephron number between racial and ethnic groups and 
geographic locations is largely unknown. Tracking fetal size by fundal height, ultrasound and doppler 
velocimetry can detect intrauterine growth restriction, but the impact of interventions during pregnancy 
or soon after birth on CKD risk is unknown. Similarly, the impact of PTB on CKD requires longitudinal 
studies. The impact of HBW on CKD risk has rarely been studied. Better methods to screen for and treat 
pre-eclampsia and consequences require further study.  
 
Action strategies: The impact of fetal and early life development on risk of adult NCDs is 
underappreciated. Monitoring the incidence of LBW, HBW, PTB and fetal growth restriction is required 
to understand the burden by region and to raise awareness of potential long-term risks. Identification of 
regional and demographic disparities in birth weights or PTB within countries requires specific 
interventions or intensification of prevention efforts. Babies must be weighed at birth or soon 
thereafter, and the birth weight and gestational age should be documented in an enduring health 
record, which is often not done in LMIC.113,127 Similarly neonatal AKI should also be documented as a risk 
factor for future CKD and trigger follow-up. Education of the public, HCW and traditional birth 
attendants is required to raise awareness of the long-term risks of LBW, growth restriction, PTB, GDM 
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and pre-eclampsia for mother and child. Both require early and ongoing education about healthy 
lifestyles and lifelong follow-up. Engagement with mothers, communities, traditional birth attendants 
and HCW is important to encourage optimal feeding of LBW, HBW, SGA and preterm children to ensure 
healthy growth while avoiding obesity. Ensuring access to essential healthcare and medications is crucial 
to optimize child and maternal health.  
 
Given the attention focused on improvements in maternal and child health initiated by the Millennium 
Development Goals (MDG) and Sustainable Development Goals (SDG), most countries have some form 
of data reporting or monitoring.128 Policies should not focus only on maternal health during pregnancy 
and at delivery, but include access to family planning, equity and education for women, reduction of 
poverty and access to better nutrition. Monitoring of women throughout pregnancy is important to 
detect and manage problems early. Innovative programs have improved prenatal clinic visits and 
deliveries attended by skilled birth attendants.129 Such programs should be utilized to improve 
documentation of birth circumstances, maternal pre-eclampsia or GDM, thereby identifying individuals 
requiring long-term follow up and to initiate life-style education peri-partum. In LMIC engagement with 
traditional birth attendants is important to build trust and educate them to detect and refer problem 
cases. Women with pre-eclampsia should be followed long-term to determine the impact of 
interventions to reduce their long-term CVD and CKD risks. 
 
Infections as risk factors for CKD 
CKD and AKI are considered NCDs, but infections are an important cause of both conditions, especially in 
LMIC. Infections are also a common cause of AKI worldwide.63,130,131 The three diseases that received 
much attention under the MDGs, HIV, malaria and tuberculosis (TB), all can cause CKD. In 2015, 36.7 
million people were living with HIV.132 The risk of HIV nephropathy (HIVAN) varies from under 10% 
percent to almost 50% in Africa.133 HIVAN is a well-recognized form of CKD that can be prevented and 
treated with access to effective antiretroviral therapy (ART).133,134 However, the impact of ART on kidney 
disease is not straightforward. Although ART reduces the incidence and rate of HIVAN progression to 
ESKD, it also reduces the competing risk of death, therefore the prevalence of HIVAN-ESKD tends to 
increase in treated populations.133 ART does not reduce the incidence/rate of progression of non-HIVAN 
forms of CKD.133 Kidney disease prevention in HIV infection is also impacted by comorbidities such as 
diabetes and viral hepatitis and, therefore, requires additional management and health screening 
programs.133,134 In 2015, 241 million cases of malaria were reported worldwide. AKI secondary to malaria 
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occurs in up to 40% of adults with severe infection.135 Although kidney function typically recovers in 
survivors, severe AKI may eventually lead to CKD.135-137 A Sri-Lankan study also reported an association 
of malaria with risk of CKDu.138 Malaria-associated AKI can be prevented by widespread vector control, 
use of insecticide-treated bed nets and access to rapid diagnosis and treatment.135 In 2014, 9.6 million 
people became infected with TB.139,140 Genitourinary TB may be a cause of CKD through miliary 
involvement or urinary obstruction and may occur in 27% of cases of extra-pulmonary TB.141,142 HIV and 
TB infections frequently coexist, therefore the combined kidney risk, exacerbated by medication 
toxicities and interactions may be higher.  
 
Many infections other than HIV, malaria, and TB increase CKD risk. Impetigo is frequent in adults and 
children living in disadvantaged conditions. The risk of CKD among adults with impetigo is high, strongly 
supporting proactive prevention and early treatment of skin infections as a possible means to reduce 
CKD risk.143 The worldwide prevalence of hepatitis B (HBV) was 331 million people in 2013 and that of 
hepatitis C (HCV) was 148 million.144 The global risk of HBV-associated CKD is likely under 10%, whereas 
the risk of HCV-associated CKD is likely higher.145,146 HBV- and HCV-associated CKD may be unrecognized 
contributors to “chronic glomerulonephritis” which is a leading cause of ESKD in LMIC. Other infections, 
such as leptospirosis and schistosomiasis are neglected tropical diseases associated with CKD.136,147 
Given the direct associations between infections, AKI, and CKD, it is likely that strategies to prevent 
infection will reduce the global CKD burden. 
 
Gaps: The magnitude of regional CKD burden related to specific infections is unknown. How increasing 
the effectiveness and reach of public health interventions could reduce the CKD burden requires study. 
The impact of the successful treatment of malaria on the incidence of malaria-associated AKI should be 
tracked as fewer people may develop endemic immunity and may be more susceptible to severe 
disease. 
 
Action strategies:  Many guidelines mention CKD as a risk factor for infections, but few recognize CKD as 
a complication. A survey of existing guidelines is necessary to gauge current level of awareness and 
intervention for infection as a CKD risk factor. HBV vaccination, for example, successfully reduced the 
incidence of childhood HBV-associated membranous nephropathy.148 Efforts should be made to ensure 
access to vaccinations to reduce infection-associated risks of AKI and CKD. Short- and long-term 
surveillance for kidney disease in regions where these vaccines are implemented should be conducted 
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to determine the impact. Where the CKD burden associated with a specific infection is high, research is 
required to develop locally effective and sustainable methods to prevent and treat these infections. 
Such strategies require partnerships with local policy makers, public health practitioners, governmental 
organizations and communities to raise awareness and develop implementation strategies. HCWs and 
communities should be educated about the risks of AKI and CKD with infections to support prompt 
diagnosis, institution of intravenous fluids and antibiotics, and avoidance of NSAIDS and other 
nephrotoxins. Governments should suppress use of counterfeit drugs, which contribute to increasing 
disease severity and increase risk of AKI in infections.  
 
AKI as a risk factor for CKD  
Worldwide approximately 20% of patients admitted to hospitals develop AKI.149 This statistic is largely 
derived from high-income countries where the majority of AKI is hospital-acquired. The true AKI 
incidence in LMIC is less well known but is likely at least as high.149,150 Worldwide it is estimated that 2 
million people die of AKI annually.151 The number of AKI survivors is unknown and a considerable 
proportion will develop CKD.152-154 
 
Gaps: The actual risk of CKD after AKI is not known. Risk modifiers and the long-term impact of AKI 
prevention on the CKD burden are unknown. 
 
Action strategies: Regionally-adapted strategies should be promoted to avoid AKI. Given that most AKI in 
high-income countries is hospital-acquired, efforts to reduce AKI incidence should focused on increasing 
awareness among clinicians and encouraging proactive patient management. Strategies may include 
EMR alerts for AKI risk and medication prescribing.67,68,155 In LMIC, the majority of AKI is community-
acquired suggesting that prevention should start before hospital admission. Strategies include 
implementation of public health measures to reduce risk of infections and use of nephrotoxins; ensure 
access to clean water; reduce poverty, accidents and trauma; improve maternal health; and provide 
access to essential healthcare and medication. Education campaigns should be conducted in 
communities and among HCWs to increase awareness of AKI risk, avoid nephrotoxins and seek 
healthcare promptly.156 Once patients present to a hospital, guidelines and facilities should be available 
to institute appropriate therapy. Long-term follow up of patients with AKI is required to determine true 




Morbidity and mortality from CKD are increasing worldwide, and CKD is progressively being recognized 
as an important contributor to the global burden of disease.1,7  Major contributors to the CKD burden 
are the growing frequencies of diabetes, hypertension and obesity, well-established traditional risk 
factors for CKD. Public health policies directed towards addressing many life-style factors that contribute 
to these conditions would be expected to positively impact the risk of CKD. Systematic screening for CKD 
in at-risk individuals is required for timely intervention when needed and to understand the impact of 
such policies on CKD incidence. The contribution of non-traditional CKD risk factors, including 
nephrotoxin exposure, kidney stones, fetal and maternal factors, infections, environmental factors and 
AKI, to the global CKD burden is unknown. Moreover, many non-traditional risk-factors may 
predominate in LMIC. The impact of reducing non-traditional CKD risk factors requires study. Mitigation 
of non-traditional CKD risk factors will require advocacy efforts to support policy development, 
implementation of strategies to reduce disparities, improve access to essential healthcare and maternal 
and child health, reduce environmental exposures, prevent AKI, better understand traditional remedy 
use, and prevent infections.2,3,157 Race/ethnicity, genetics, sex, socioeconomic status, and geography 
likely modify the impact of CKD risk factors. Effective coordination within health systems, and 
importantly in the era of the SDGs, a broad multi-sectoral approach are required to identify and tackle 
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Abbreviations: ACEI – angiotensin converting enzyme inhibitor; AKI – acute kidney injury; ARB – angiotensin receptor blocker; ART – anti-retroviral therapy; BMI – body mass index; BP –blood 
pressure; CKD – chronic kidney disease; CKDu – chronic kidney disease of uncertain aetiology; CVD – cardiovascular disease; DM – diabetes mellitus; GDM – gestational diabetes mellitus; GFR – 
glomerular filtration rate; GN – glomerulonephritis; ESKD – end stage kidney disease; HAART – highly active anti-retroviral therapy; HIC – high income country; HIV – human immunodeficiency virus; 
HCV – hepatitis C Virus; ITN – insecticide-treated nets; LBW – low birth weight; LMIC – low middle income country; MDR – multi-drug resistance; NSAID – non-steroidal anti-inflammatory drug; OTC – 
over the counter; PEP – post-exposure prophylaxis; PPI – proton pump inhibitor; PSGN – post-streptococcal glomerulonephritis; Rx – treatment; SDG=Sustainable Development Goal; SGA – small for 
gestational age; TB – tuberculosis; UHC - Universal Health Care; UMIC – upper middle income country; XDR – extensive drug resistance. 
 
 
 
